At present, mutation of the p53 gene appears to be the most common genetic alteration found in human cancers. These mutations can occur within many different regions of the gene. We have developed a modification of denaturing gradient gel electrophoresis termed "constant denaturant gel electrophoresis" (CDGE), which provides a rapid and sensitive method to screen the four conserved regions within the p53 gene where the majority of p53 mutations have been reported. The sensitivity of CDGE was first tested with known p53 mutations in all four conserved regions. The CDGE technique was then used to screen 32 breast carcinomas that had been analyzed by immunohistochemical methods for altered p53 protein levels and whose DNA had already been shown to have loss of heterozygosity for a chromosome 17p marker. By immunostalning techniques, only 6 of the 32 tumors had elevated p53 expression. However, CDGE detected p53 mutations in 11 of the 32 tumors. DNA sequence analysis was performed to determine the nucleotide positions of these mutations in all 11 samples. Loss of heterozygosity for the pYNZ22 or pl44D6 markers did not associate with either the loss of heterozygosity at the p53 locus or the mutations detected by CDGE. We conclude that CDGE is a rapid and effective technique to screen for p53 mutations.
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A wide variety of human tumors have been shown to be associated with changes in the p53 gene (1) (2) (3) (4) (5) (6) (7) (8) . As the list of cancers with p53 mutations increases, there is a need for an accurate and rapid screening technique for these mutations. Unlike some of the dominant oncogenes, p53 can be inactivated by a diverse set of mutations scattered through several important regions of the gene (7) . Many recent surveys of p53 mutations have used loss of heterozygosity (LOH) at polymorphic markers closely linked to p53 as an indirect assay for p53 inactivation (9) (10) (11) . While such a screen is rapid, it cannot detect point mutations, and its accuracy is limited, since some of the nearby polymorphic markers might undergo deletions that do not extend into the p53 locus. Alternatively, because mutations in the p53 gene frequently result in a mutant p53 protein that is significantly overexpressed compared with the low levels of the wild-type protein, other p53 surveys have used immunostaining techniques to screen for mutations (12) (13) (14) . Unfortunately, the p53 mutations that result in either a lack of protein or the same low levels of p53 as are present in cells containing the wild-type p53 cannot be detected by this method. The most sensitive screening technique is to sequence the genomic region encoding p53. Although sequencing is quite sensitive, it is also laborintensive. There are several new nucleic acid-based screening methods that can rapidly detect mutations within short fragments of DNA. These techniques include RNase protection assays (15) , single-strand conformational polymorphisms (SSCP) (16, 17) , denaturing gradient gel electrophoresis (DGGE) (18, 19) , and detection of base-pair mismatches with hydroxylamine and osmium tetroxide (20) .
To develop a screening method for p53 mutations, we have tested a modification of the DGGE system (18) , termed constant denaturant gel electrophoresis (CDGE) (21 (22) . Thirtytwo of the samples that had LOH for at least one of a panel of 17p markers were used for CDGE analysis.
DNA Analysis and Tissue Immunostaining. DNA was extracted from cell nuclei of tumor tissue and whole blood by standard procedures (phenol/chloroform extraction and ethanol precipitation). Allelic loss of chromosome 17p sequences in tumors was analyzed by Southern blot hybridization using a series of polymorphic probes (22) . Frozen sections from the breast carcinomas were immunostained with a polyclonal antibody against p53 that recognizes both wild-type and mutant p53 (OM-11-918; Cambridge Research Biochemicals).
Abbreviations: CDGE, constant denaturant gel electrophoresis; DGGE, denaturing gradient gel electrophoresis; LOH, loss of heterozygosity. tTo whom reprint requests should be addressed.
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Polymerase Chain Reaction (PCR). DNA from 32 tumor tissue samples, all with LOH ofeither ofthe previously tested 17p markers, and from 6 samples with known mutations was subjected to mutation analysis using PCR followed by CDGE. Three of these samples (LF1-LF3) were DNA extracted from patients with Li-Fraumeni syndrome (26) . The other three samples were from sporadic tumors (33) . The DNA fragments that were amplified are shown in Fig. 1 together with the position and type of the previously identified mutants. PCR was performed using 100-300 ng of template DNA in 50 mM Tris'HCI, (pH 8.6) with 10 mM KCI, 1.5 mM MgCl2, 0.2 mM each dNTP, 25 or 100 pmol of each primer (25 of the purified and 100 of the unpurified), and 2.5 units of Taq polymerase (AmpliTaq, Cetus). The 100-j I mixture was incubated in a Perkin-Elmer/Cetus thermocycler for 35 cycles of 940C (45 sec), 550C (45 sec), and 720C (45 sec). The reaction was initiated with one 7-min incubation at 940C and ended with a 10-min incubation at 72TC. The primers were synthesized by Genosys (Houston), and only the 60-mer primers were ordered purified. The primers were designed using the OLIGO primer analysis program from National Biosciences. A "GC clamp" was attached to one of the primers in each set, creating a 60-mer primer (19) All the PCR products were analyzed for purity by 7.5% PAGE followed by staining with ethidium bromide. Denaturing Gel Electrophoresis. The theoretical melting profiles of the amplified fragments were produced by the computer program of Lerman et al. (23), based on the statistical mechanical principles and algorithms developed by Poland (24) and the nearest-neighbor base-pair doublet parameters introduced by Gotoh and Tagashira (25) .
Perpendicular denaturing gradient gels (10 x The gradient gels were cast with a gravitational gradient mixer. All reagents used were of electrophoretic grade. The PCR product was loaded into a long well along the top of the gel and run with the electrophoresis direction perpendicular to the denaturant gradient. Gels were run submerged in TAE buffer at 56.00C at 80 V constant, in a self-constructed cell adapted to the Mini-Protean electrophoresis-cell system (Bio-Rad). The modification allowed the glass plates surrounding the gels to be in direct contact with the buffer on both sides. Extensive circulation of the buffer was provided during the runs. The running time was 1-2 hr. After electrophoresis, the gels were stained for a few minutes with ethidium bromide (2 mg/liter of TAE) and photographed using a UV transilluminator. Sequencing. A 1.7-kilobase fragment was generated from 0.5-2.0 ,ug of the genomic DNA template. This fragment was subcloned and sequenced with four pairs of internal primers as described (26) . RESULTS LOH Studies of Chromosome 17 Markers and Immunostining of p53. The LOH for the various chromosome 17 markers used in this study have been reported (22) . LOH of either of the 17p markers tested was observed in 32 tumors. The most frequently lost marker was p144D6 (25/29, 86.2%) followed by pYNZ22 (21/26, 80.8%) and p53 (9/16, 56.3%).
Immunostaining of frozen sections showed that 6 of these 32 tumors (18.8%) had elevated p53 protein levels compared with normal tissues. All of the 6 tumors had LOH of pYNZ22 or p144D6 ( Table 1 ), suggesting that these deletions were associated with elevated levels of p53. Surprisingly, for the 4/6 of these samples with elevated levels of p53 that were informative at the p53 locus itself, only 2 samples had LOH at the p53 locus. The 2 tumors with overexpression and with no LOH of p53 had LOH of pYNZ22, and one had LOH of p144D6 but the other did not. There is clearly a lack of correlation between these two tests. To determine which values are the false positive and negative ones, it appears to be important to actually screen for p53 mutations.
Development of a Screening Technique for p53 Mutation Analysis. Prior to CDGE analysis, theoretical melting maps were calculated for the four regions in p53 where >80%o ofthe reported mutations cluster. Primers were designed for each region-to give fragments with melting profiles with high-and low-melting domains, where most of the region to be screened resided in the low-melting area. A total of 321 base pairs encoding 107 amino acids resided in lower-melting domains between the primers used for amplification (Fig. 1) . Previous studies (19, 21, 23) have shown that using a GC clamp increases the number of detectable mutations from 40%o of all single base changes to close to 100%, if they reside in the lower-melting domains of the fragment. Most of the mutations in these codons (Fig. 1) should therefore be detected by our CDGE system.
The theoretical melting profiles of six previously identified mutants are shown in Fig. 1 In Fig. 2 , the actual melting behaviors of four fragments containing previously identified mutations are compared with the melting behavior of wild-type DNA in perpendicular denaturing gradient gels. The observed strand separation indicates that mutant DNAs can be distinguished from the wild-type DNA. When both normal and mutant fragments were present in the same sample, heteroduplex formation was often observed (Fig. 2 B and C ). An artifact that was seen at times is shown in Fig. 2C : a shadow curve that migrated faster than, but was parallel to, the normal band. The presence of this shadow band correlated with freezing and thawing of the long primer and was probably due to breakage within the G-C region.
We then tested the six mutants by CDGE. The denaturant concentration used for each region was determined from the theoretical melting curve and from the perpendicular gels ( Figs. 1 and 2 ). For region A, the optimal concentrations were 42.5% and 50.7%. For region B only one denaturing concentration was used (51.7%); for regions C and D two denaturant concentrations were used (32% and 50.7%). With these conditions, CDGE was successful in separating all of the six previously identified mutants from the wild type (Fig. 3) . The multiple bands in Fig. 3C represent heteroduplexes between the mutant and normal p53 amplified fragments.
CDGE Analyses of Tumors. Tumor DNA from 32 carcinomas, each with LOH of a 17p marker and previously analyzed by immunostaining for p53, was then analyzed for mutations in all four regions. Representative gels showing tumors with p53 mutations compared to tumors without such mutations are shown in Fig. 4 . Each of 11 tumor samples yielded a PCR product with a mobility different from normal DNA, indicating a mutation residing in one of these fragments. The approximate position and the nature of the mutations could be predicted from these gels. For example, tumor T29 (Fig.  4A ) migrated more slowly and hence would be predicted to have undergone a G-C --APT mutation, because such a Table 1 for the nature of the mutations found in the tumors. mutation would result in the destabilizing loss of a hydrogen bond. All the tumors with mutations identified by CDGE were subjected to sequence analysis to confirm the mutations and to determine their exact nature (Table 1 ). In one tumor (T34) a silent mutation (Pro Pro) was observed, indicating that tumors with aberrantly migrating bands on CDGE may not always have mutations that result in an amino acid change. In the two tumors with elevated p53 expression but without LOH of p53, no p53 mutation was detected by CDGE, suggesting that the overexpression of the wild-type p53 might be modulated by other factors. Sequencing could not be performed because there was not sufficient DNA. Mutations not detectable by our CDGE technique or mutations outside the screened regions could not be excluded. Four of the 11 tumors (36.4%) with p53 mutations detected by CDGE showed elevated levels of p53 protein compared with normal tissues, yet 2 of 21 tumors (9.5%) without detectable mutations had elevated levels of p53. All of the tumors with mutations had LOH of p53 when informative. Three of 10 tumors with no mutations and 1 with a silent mutation had LOH ofp53. These four tumors seemed to have lost a whole chromosome 17 since all of the markers on both 17p and 17q showed LOH (22) . DISCUSSION CDGE appears to be a rapid, efficient, and reliable method to screen for unknown mutations in the p53 gene in human breast carcinomas. Our results indicate that 34% of breast tumors with LOH of a 17p marker had p53 mutations detectable by CDGE using four fragments covering the regions where the majority of p53 mutations are found.
Several investigators have reported significant LOH of chromosome 17 sequences in human breast carcinomas (11, 22, (27) (28) (29) . There appear to be two regions of overlap on the short arm that are frequently lost. One region, in band 17p13.3, contains probes pYNZ22 and p144D6, and the other region, containing the p53 gene, is located 20 centimorgans centromeric to the first region. Using the combined set of data for LOH of loci at 17p, we found a highly significant association between p53 mutations and LOH at the p53 locus (P = 0.011), whereas no significant association was found between p53 mutation and LOH of the other two 17p markers. This confirms and expands on previous data suggesting that the LOH of 17p markers involves more than deletions of the p53 gene (27, 30) . The data also indicate that loss of the wild-type p53 allele might be necessary for tumorigenesis in certain organs.
Two of the six samples with increased p53 expression levels have retained heterozygosity for the p53 locus. No p53 mutations were found in these samples by CDGE screening with the four primer sets (Fig. 1) . However, both tumors have LOH for pYNZ22. It is therefore tempting to speculate that one reason for the increased p53 expression is the loss of a controlling gene at pYNZ22, with a mechanism of tumorigenesis that does not involve mutation of the p53 gene.
Mutations found in the p53 gene in human carcinomas so far seem to cluster primarily in four "hot spots," all residing in the highly conserved region of the gene (encoding amino acids 118-280) (7, 31) . To date, several methods have been available for rapid screening of point mutations in regions of interest in the human genome. Each ofthese previous screening methods has features that make it potentially less than optimal. The hydroxylamine/osmium tetroxide technique will not detect A -* T or T --A changes (20 In the present series ofbreast tumors, 3 of the 11 sequenced mutations (T6, T83, T112) were found where CpG sequences are located. These positions have been shown to be methylated in human tissues (31) . The majority of reported mutations at these positions are consistent with a mechanism of induction of methylcytosine deamination leading to C -+ T or G --A transitions. The mutations analyzed by Prosser et al. (32) , and the mutations presented here indicate that the clustering of mutations in breast carcinomas are less conspicuous than reported for colorectal tumors (7) .
Screening for p53 gene mutations in the germ line, in premalignant lesions, in primary tumors, and in metastases may help answer the question of the importance of different mutations and the behavior ofthe tumor. CDGE seems to offer a rapid technique by which to screen for such mutations. These may help to elucidate the sequence ofevents that occurs in tumorigenesis and to determine the role of p53 in that process.
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